Stocktoria
Marker Therapeutics, Inc. MRKR
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-11-08
Marker Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M | $500,000 | $213,194 | $205,994 | $183,064 | — |
| R&D expense | $11.8M | $13.5M | $10.4M | $12.0M | $27.8M | $18.9M | $12.8M | $8.0M | $5.3M | $3.8M |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M | -$28.9M | -$22.5M | -$148.2M | -$11.5M | -$8.5M |
| Income tax | -$15,156 | $49,953 | $3,675 | — | — | — | — | $0 | $0 | $0 |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M | -$28.7M | -$21.4M | -$148.0M | -$11.0M | -$2.5M |
| EPS (diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-0.61 | — | — | $-1.16 | $-0.72 |
| Operating cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M | -$20.0M | -$18.3M | -$14.5M | -$8.4M | -$6.5M |
| Free cash flow | — | — | — | — | — | — | -$18.7M | -$14.6M | -$8.4M | — |
| Cash & equivalents | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M | $21.4M | $43.9M | $61.7M | $5.1M | — |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M | $45.6M | $46.4M | $62.1M | $5.2M | $7.9M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M | $18.3M | $2.3M | $2.8M | $1.5M | $1.7M |
| Shareholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M | $27.3M | $44.1M | $59.3M | $3.7M | $6.2M |
Growth · year-over-year · Revenue CAGR 44.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -46.2% | +99.1% | -5.8% | +183.0% | +148.3% | +134.5% | +3.5% | +12.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.